HomeLab TestsBeta 2 Microglobulin (B2M) Tumor Marker Test
Back to Lab Tests
Beta 2 Microglobulin (B2M) Tumor Marker Test
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Lab Tests

Beta 2 Microglobulin (B2M) Tumor Marker Test

The B2M tumor marker test measures a specific protein in body fluids to help monitor blood and bone marrow cancers and evaluate kidney function.

What is a beta-2 microglobulin tumor marker test?

A beta-2 microglobulin (B2M) tumor marker test measures the amount of a protein called beta-2 microglobulin in your body fluids, typically blood, though it may also be done using urine or cerebrospinal fluid (CSF). B2M is a small protein found on the surface of most cells. While healthy kidneys filter B2M out of the blood, high levels can act as a tumor marker for certain cancers, including:

  • Multiple myeloma
  • Chronic lymphocytic leukemia (CLL)
  • Certain types of lymphoma

High levels can also be caused by noncancerous conditions like kidney disease and autoimmune disorders. Because of this, the test is not used to diagnose cancer but is instead performed after a diagnosis to provide information about the disease.

What is it used for?

Testing B2M levels helps providers:

  • Determine how much the cancer has grown or spread.
  • Predict how the cancer might progress over time.
  • Select treatments and monitor their effectiveness.
  • Check whether cancer has spread to the brain or spinal cord.

Why do I need a beta-2 microglobulin tumor marker test?

You may need this test if you have been diagnosed with multiple myeloma, chronic lymphocytic leukemia, or certain types of lymphoma. It helps determine the severity of the disease and monitors how well your treatment is working. In cases of multiple myeloma, a urine test may be used to see if the disease is affecting your kidneys.

What happens during a beta-2 microglobulin tumor marker test?

The test usually involves a blood sample. In some cases, a 24-hour urine sample or a cerebrospinal fluid (CSF) analysis via a spinal tap may be required. For a blood test, a professional draws blood from a vein in your arm. For a 24-hour urine sample, you collect all urine over a full day in a provided container. For a CSF analysis, a provider performs a spinal tap to remove fluid from your lower spine.

Will I need to do anything to prepare for the test?

There are no special preparations for blood or urine tests. For a CSF analysis, you may be asked to empty your bladder and bowels before the procedure.

Are there any risks to the test?

Blood tests carry very little risk, typically limited to slight pain or bruising. Urine tests have no known risks. A spinal tap may cause a pinch or pressure during the procedure, and potential side effects include back pain, tenderness, bleeding, or a headache that may last for several days.

What do the results mean?

If used to evaluate cancer, higher B2M levels generally indicate more cancer in the body and are linked to faster-growing cancers. When monitoring treatment:

  • Increasing B2M levels may mean treatment is not working.
  • Decreasing B2M levels may mean treatment is working.
  • Stable B2M levels may mean the disease is stable.

Is there anything else I need to know about a beta-2 microglobulin tumor marker test?

Because B2M levels can be elevated by noncancerous conditions, providers may use this test for other purposes, including:

  • Checking kidney function: High levels may be an early sign of kidney injury.
  • Monitoring immune and autoimmune diseases: Increased levels may indicate an overactive immune system, such as in Sjogren's syndrome.
  • Detecting transplant rejection: High levels in liver transplant patients may signal organ rejection.
  • Evaluating dialysis treatment: Helps check how well the dialysis filter is working.

Frequently Asked Questions

Beta-2 microglobulin is not specific to cancer, so elevated levels can be caused by several non-cancerous conditions. The most common non-malignant cause is kidney disease, as the kidneys are responsible for filtering B2M from the blood; if kidney function declines, B2M accumulates in the bloodstream. Other causes include autoimmune disorders like rheumatoid arthritis, chronic infections, and inflammation. Because of this, a high B2M level alone cannot diagnose cancer and must be evaluated in the context of other clinical findings and tests.
Yes, measuring B2M in cerebrospinal fluid (CSF) can be useful in certain contexts, particularly for lymphomas. If there is a significant difference between B2M levels in the blood and the CSF, or if CSF B2M is markedly elevated, it may suggest that cancer cells have spread to the central nervous system. This test is usually performed via a lumbar puncture and is ordered when there is clinical suspicion of CNS involvement, helping to guide decisions about whether intrathecal chemotherapy or other targeted treatments are necessary.
The frequency of B2M testing depends on your specific cancer type and treatment plan. For conditions like multiple myeloma, it is often used as part of the International Staging System to assess prognosis and may be checked at diagnosis, before treatment begins, and periodically during follow-up to monitor response. Your oncologist will determine the schedule, which might range from every few months to annually, to track whether the protein levels are decreasing, which typically indicates that the treatment is working.
No, the beta-2 microglobulin test does not require fasting or any special dietary preparation. It is a standard blood draw, and you can eat and drink normally before the appointment. However, you should inform your healthcare provider about any recent illnesses or changes in kidney function, as these can temporarily alter B2M levels and potentially skew the interpretation of your cancer monitoring results.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss